FOLH1 and prostate carcinoma: The study demonstrated that TCL-SPION-Apt conjugate functioned as an MRI contrast agent, permitting the detection of PSMA-positive prostate cancer cells with high sensitivity, and selectively inducing Doxorubicin cytotoxicity into target cells in vitro.